Skip to content
Triangle logo TriangleGet started
← All settings

DISEASE & TREATMENT SETTING

Avopef: refractory Testicular Cancer

Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.

Exact scope

1.1 Refractory Testicular Cancer AVOPEF, in combination with chemotherapy, is indicated for the treatment of refractory testicular cancer in adult patients.

Broader topic: Testicular Cancer

Source population
Not part of this definition
Disease extent
refractory
Treatment line
Not part of this definition
Stage
Not part of this definition
Resectability
Not part of this definition
Biomarkers, prior therapy and derivation
molecular
    prior therapy
      derivation status
      source-attested
      derivation note
      Scoped from the FDA approved indication for Avopef (product label). Only dimensions stated in that wording are part of this definition.
      source wording
      1.1 Refractory Testicular Cancer AVOPEF, in combination with chemotherapy, is indicated for the treatment of refractory testicular cancer in adult patients.

      Study evidence for this setting

      8 linked studies · Applicability is a draft source assessment, not a determination of your eligibility.

      NCT00183820 · Registry condition search · Scope: unclear

      Study of Gemcitabine, Oxaliplatin, and Paclitaxel in Patients With Refractory Germ Cell Carcinoma

      3 outcome links · 1 safety-group records · 0 quality-of-life measures

      →

      NCT00408681 · Registry condition search · Scope: unclear

      Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant

      6 outcome links · 1 safety-group records · 0 quality-of-life measures

      →

      NCT00536601 · Registry condition search · Scope: unclear

      High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors

      4 outcome links · 5 safety-group records · 0 quality-of-life measures

      →

      NCT00795769 · Registry condition search · Scope: unclear

      Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant

      1 outcome links · 1 safety-group records · 0 quality-of-life measures

      →

      NCT00957905 · Registry condition search · Scope: unclear

      Alvocidib and Oxaliplatin With or Without Fluorouracil and Leucovorin Calcium in Treating Patients With Relapsed or Refractory Germ Cell Tumors

      4 outcome links · 2 safety-group records · 0 quality-of-life measures

      →

      NCT01159067 · Registry condition search · Scope: unclear

      Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload

      4 outcome links · 1 safety-group records · 0 quality-of-life measures

      →

      NCT02499952 · Registry condition search · Scope: unclear

      Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors

      4 outcome links · 1 safety-group records · 0 quality-of-life measures

      →

      NCT02689219 · Registry condition search · Scope: unclear

      Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors

      4 outcome links · 2 safety-group records · 0 quality-of-life measures

      →
      Source relationships and population-mapping limitations
      bindings
        mappings

          Download this complete draft source relationship record →

          Preserved source evidence · Not medical advice